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Methods 
• We hypothesize that the various markers will stain in similar patterns
with both chromogenic IHC and CODEX, and that the antibodies will
correctly recognize various lymphoid, myeloid, structural and immune
cells in order to effectively depict the immunoprofile.
Figure 1. Workflow of the application of the CODEX panel. 
Results
































































































• Individual antibody optimization by Immunohistochemistry
• Antibody conjugation with their oligonucleotide
• Gel electrophoresis testing to validate proper conjugation
• Individual antibody staining in CODEX 
• Group the antibodies in cycles and staining 
Figure 2. Antibodies included in the CODEX panel. 
• We successfully optimized the various markers to obtain similar 
staining patterns with both chromogenic IHC and CODEX. PD-
L1 was predominantly expressed on the cell membranes of 
epithelial cells on tonsil tissue. Other immune checkpoint 
proteins were observed in various immune cells. In control tonsil, 
CK was expressed by epithelial cells, and among cells 
surrounding the germinal centers, the T cell marker CD3 was 
most abundant, followed by CD8, Granzyme B, CD45RO, 
FOXP3. PD-1 was predominantly distributed within the germinal 
center of the tonsil tissue. We are continuing to test the other 
markers in the panel.
• Multiplexed immunophenotyping approaches reveal key insight 
into identifying therapeutic mechanisms. A comprehensive 
immunoprofile will advance our understanding of how various 
factors can determine disease progression, resistance and 
response to immunotherapies and facilitate the development of 
new treatment approaches.
• Cancer immunotherapy is revolutionizing cancer treatment by aiding 
the natural ability of the immune system to identify and defend against 
tumors.
• In order to better design cancer therapeutics and advance clinical care, 
the immunoregulatory proteins involved in immune checkpoints and 
immunosuppression must be immunoprofiled.  
• We used highly multiplexed tissue imaging technologies, such as 
CODEX (CO-Detection by indEXing), which allows more than 40 
antibody markers to be placed and analyzed on tissues.
• Herein, we describe the optimization, validation and application of a 27-
antibody panel used for multiplexed immunophenotyping. 
Figure 3. Heat map showing the presence of various markers in different cell-types. 
Figure 4. Percent of immune and tumor cells that 
express various immunoregulatory proteins. 
